Sanara MedTech acquired by MiMedx Group: fairness opinion
Announced July 29, 2026 · Merger ·
DEFM14A filed September 4, 2026
Enterprise value
$350M
EV / LTM EBITDA
20.6x
EBITDA $17.0M · 16% margin
EV / LTM revenue
3.39x
revenue $103M
DCF discount rate
12.1%–14.1%
Deal terms
Consideration—
Price per share—
Premium—
Premium basis—
StructureMerger
Termination fee—
Reverse termination fee—
Go-shopNone
Outside date—
FilingDEFM14A · EDGAR index
3,000+ healthcare deal-level valuation multiples
The Valuation database includes financial details for more than 3,000 healthcare M&A transactions, private and public, with deal-level multiples, categorized by segment, type, and year.
Management projections
| Projection year | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | $121M | $151M | $186M | $236M | $297M | 25.2% |
| Revenue growth | 17.4% | 24.7% | 23.1% | 26.7% | 26.3% | |
| EBITDA | $21.5M | $32.1M | $44.1M | $63.4M | $87.7M | 42.1% |
| EBITDA growth | 26.5% | 49.3% | 37.4% | 43.8% | 38.3% | |
| EBITDA margin | 18% | 21% | 24% | 27% | 29% | |
| Implied EV / EBITDA | 16.3x | 10.9x | 7.9x | 5.5x | 4.0x |
Year-1 growth is against LTM at announcement ($103M revenue, $17.0M EBITDA); later years are year over year.
Other Medical Devices and Supplies fairness opinions
- Integer / KKR 2026 · 14.6x EV/EBITDA
- Avanos Medical / American Industrial Partners 2026 · 14.7x EV/EBITDA
- Penumbra / Boston Scientific 2026 · 57.7x EV/EBITDA
- Varex Imaging / Teledyne Technologies 2026 · 9.4x EV/EBITDA
- Hologic / Blackstone / TPG 2025 · 14.1x EV/EBITDA
- ZimVie / ARCHIMED 2025 · 10.8x EV/EBITDA